Hydroxychloroquine in Stage 1 Type 1 Diabetes

To test whether blocking innate immaune cells modulated progression of the disease, we randomly assigned 273 individuals with stage 1 T1D to treatment with hydroxychloroquine or placebo and assessed whether hydroxychloroquine treatment delayed or prevented progression to stage 2 T1D